Last reviewed · How we verify

Cerezyme® — Competitive Intelligence Brief

Cerezyme® (Cerezyme®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic disease / Lysosomal storage disorder.

marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase) Rare genetic disease / Lysosomal storage disorder Small molecule Live · refreshed every 30 min

Target snapshot

Cerezyme® (Cerezyme®) — ISU Abxis Co., Ltd.. Cerezyme is an enzyme replacement therapy that provides the missing glucocerebrosidase enzyme to break down glucocerebroside in patients with Gaucher disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cerezyme® TARGET Cerezyme® ISU Abxis Co., Ltd. marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase)
Myozyme® (alglucosidase alfa) Myozyme® (alglucosidase alfa) Genzyme, a Sanofi Company marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA); lysosomal glycogen
Pancrelipase Capsules Pancrelipase Capsules Ohio State University marketed Pancreatic enzyme replacement therapy
Panzytrat 25.000 FIP-E units of Lipase Panzytrat 25.000 FIP-E units of Lipase Foundation for Liver Research marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids
Replagal (agalsidase alfa) Replagal (agalsidase alfa) Shire marketed Enzyme replacement therapy α-galactosidase A (GLA)
Pegvaliase-Pqpz Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)
Pancreatic Enzyme Pancreatic Enzyme University of Oxford marketed Pancreatic enzyme replacement therapy (PERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cerezyme® — Competitive Intelligence Brief. https://druglandscape.com/ci/cerezyme. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: